Patients with Parkinson disease (PD) who harbor LRRK2 G2019S mutations may have increased risks of nonskin cancers. However, the results have been inconsistent across studies.
Ilir Agalliu, MD, ScD, of the Albert Einstein College of Medicine in the Bronx, and colleagues analyzed pooled data from 5 centers to further examine the association betweenLRRK2 G2019S mutation and cancer among patients with PD and to explore factors that could explain discrepancies.
This multinational study from 5 centers demonstrates that LRRK2G2019S mutation carriers have an overall increased risk of cancer, especially for hormone-related cancer and breast cancer in women.
READ FULL ARTICLE From archneur.jamanetwork.com